Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma. / Yao, Y.; Ali, Z.; Thomsen, S. F.

I: Drugs of the Future, Bind 46, Nr. 7, 2021, s. 529-536.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Yao, Y, Ali, Z & Thomsen, SF 2021, 'Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma', Drugs of the Future, bind 46, nr. 7, s. 529-536. https://doi.org/10.1358/dof.2021.46.7.3301491

APA

Yao, Y., Ali, Z., & Thomsen, S. F. (2021). Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma. Drugs of the Future, 46(7), 529-536. https://doi.org/10.1358/dof.2021.46.7.3301491

Vancouver

Yao Y, Ali Z, Thomsen SF. Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma. Drugs of the Future. 2021;46(7):529-536. https://doi.org/10.1358/dof.2021.46.7.3301491

Author

Yao, Y. ; Ali, Z. ; Thomsen, S. F. / Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma. I: Drugs of the Future. 2021 ; Bind 46, Nr. 7. s. 529-536.

Bibtex

@article{32057954384545c1bd91d029bef2cdc1,
title = "Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma",
abstract = "Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.",
keywords = "Tezepelumab, AMG-157, MEDI-9929, TSLP, Asthma, Atopic dermatitis, Biologics, Pharmacokinetics, Clinical study, GENOME-WIDE ASSOCIATION, IGM(+) B-CELLS, UNCONTROLLED ASTHMA, IN-VITRO, PHARMACOKINETICS, DIFFERENTIATION, TOLERABILITY, PHENOTYPE, CYTOKINE, SAFETY",
author = "Y. Yao and Z. Ali and Thomsen, {S. F.}",
year = "2021",
doi = "10.1358/dof.2021.46.7.3301491",
language = "English",
volume = "46",
pages = "529--536",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "7",

}

RIS

TY - JOUR

T1 - Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma

AU - Yao, Y.

AU - Ali, Z.

AU - Thomsen, S. F.

PY - 2021

Y1 - 2021

N2 - Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.

AB - Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.

KW - Tezepelumab

KW - AMG-157

KW - MEDI-9929

KW - TSLP

KW - Asthma

KW - Atopic dermatitis

KW - Biologics

KW - Pharmacokinetics

KW - Clinical study

KW - GENOME-WIDE ASSOCIATION

KW - IGM(+) B-CELLS

KW - UNCONTROLLED ASTHMA

KW - IN-VITRO

KW - PHARMACOKINETICS

KW - DIFFERENTIATION

KW - TOLERABILITY

KW - PHENOTYPE

KW - CYTOKINE

KW - SAFETY

U2 - 10.1358/dof.2021.46.7.3301491

DO - 10.1358/dof.2021.46.7.3301491

M3 - Journal article

VL - 46

SP - 529

EP - 536

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 7

ER -

ID: 274871668